1. Mori J, Corbau R, Lewis D, Ellery S, Mayer H, Perros M, Westby M (2008) Characterization of a NNRTI, UK-453,061 in vitro. In: 15th Conf Retroviruses and Opportunistic Infections (abstract 728). Boston
2. Vernazza P, Wang C, Pozniak A, Weil E, Pulik P, Cooper DA, Kaplan R, Lazzarin A, Valdez H, Goodrich J, Craig C, Mori J, Tawadrous M (2011) Efficacy and safety of lersivirine vs efavirenz in antiretroviral treatment-naive HIV-1-infected patients: Week 48 primary analysis results from an ongoing multicentre, randomised, double-blind, Phase IIIb trial (Study A5271015). In: 16th Int AIDS Conf on HIV Pathogenesis, Treatment and Prevention (abstract TUAB0101). Rome
3. Vourvahis M, Gleave M, Nedderman ANR, Hyland R, Gardner I, Howard M, Kempshall S, Collins C, Labadie R (2010) Excretion and metabolism of lersivirine (5-([3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1 H-pyrazol-4-yl]oxy)benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers. Drug Metab Dispos 38:789–800
4. Davis J, Langdon G, Layton G, Chong C, Ndongo M-N, Weissgerber G, Vourvahis M (2008) The effect of UK-453,061, a next-generation NNRTI, on the steady state pharmacokinetics of zidovudine, midazolam and contraceptive steroids. In: 9th Int Workshop on Clinical Pharmacology of HIV Therapy (poster P25). New Orleans
5. European Medicines Agency (2010) Guideline on the investigation of drug interactions. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC500090112.pdf